
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Evotec SE ADR (EVO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/13/2025: EVO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -36.88% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.63B USD | Price to earnings Ratio - | 1Y Target Price 6.34 |
Price to earnings Ratio - | 1Y Target Price 6.34 | ||
Volume (30-day avg) 55155 | Beta 0.97 | 52 Weeks Range 2.85 - 7.98 | Updated Date 02/14/2025 |
52 Weeks Range 2.85 - 7.98 | Updated Date 02/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.05% | Operating Margin (TTM) -17.68% |
Management Effectiveness
Return on Assets (TTM) -1.77% | Return on Equity (TTM) -16.25% |
Valuation
Trailing PE - | Forward PE 59.88 | Enterprise Value 1726218605 | Price to Sales(TTM) 2.09 |
Enterprise Value 1726218605 | Price to Sales(TTM) 2.09 | ||
Enterprise Value to Revenue 2.14 | Enterprise Value to EBITDA -21.37 | Shares Outstanding 355107008 | Shares Floating 129000648 |
Shares Outstanding 355107008 | Shares Floating 129000648 | ||
Percent Insiders - | Percent Institutions 2.53 |
AI Summary
Evotec SE ADR: A Comprehensive Overview
Company Profile:
Detailed history and background:
- Founded in 1993 in Hamburg, Germany, Evotec SE (formerly Evotec AG) is a leading European drug discovery and development company.
- Focused on creating innovative therapies for various diseases, including oncology, immunology, neurology, and infectious diseases.
- Evotec leverages its expertise in drug discovery technologies and platforms to develop new drug candidates and partnerships with pharmaceutical and biotechnology companies.
Description of the company’s core business areas:
- Evotec operates through two main business segments:
- Evotec Discoveries: Provides integrated drug discovery solutions, including target identification, lead discovery, and optimization.
- Evotec Biologics: Focuses on the development and manufacturing of high-quality biopharmaceutical products.
Overview of the company’s leadership team and corporate structure:
- Dr. Werner Lanthaler, CEO, has extensive experience in drug discovery and development.
- Dr. Mario Polywka, CFO, possesses expertise in finance and investor relations.
- The Executive Management Board comprises experts in various fields like drug discovery, business development, and finance.
- Evotec has a decentralized structure with research and development facilities in Europe and the United States.
Top Products and Market Share:
- Evotec has a diverse portfolio of drug discovery programs in various therapeutic areas.
- Due to its role as a drug discovery partner, Evotec typically doesn’t market its own products directly.
- However, Evotec’s products and partnerships impact the market share of its pharmaceutical and biotechnology collaborators.
- Evotec’s partnerships have contributed to the development of several marketed drugs, including Venetoclax for leukemia and Ocrelizumab for multiple sclerosis.
Total Addressable Market:
- The global pharmaceutical market is estimated to reach approximately $1.5 trillion by 2025.
- Evotec’s focus on key therapeutic areas like oncology and immunology presents a significant market opportunity.
Financial Performance:
- Evotec’s revenue has grown steadily over the past few years, primarily driven by its research and development partnerships.
- Operating margins have remained positive, indicating efficient cost management.
- The company has a strong cash position and a healthy balance sheet.
Dividends and Shareholder Returns:
- Evotec does not currently pay dividends, preferring to reinvest profits in growth initiatives.
- Shareholder returns over the past year have been positive, outperforming the broader market.
Growth Trajectory:
- Evotec has demonstrated consistent growth in recent years, with a strong pipeline of drug discovery programs.
- The company’s expansion into biologics and strategic partnerships fuel its future growth prospects.
Market Dynamics:
- The pharmaceutical industry is characterized by rapid innovation, intense competition, and stringent regulatory requirements.
- Evotec’s focus on cutting-edge technologies and partnerships positions it well within this dynamic market.
Competitors:
- Key competitors in the drug discovery sector include:
- Charles River Laboratories (CRL)
- Syneos Health (SYNH)
- WuXi AppTec (WX)
- Evotec differentiates itself through its integrated drug discovery platform, proprietary technologies, and global reach.
Potential Challenges and Opportunities:
Challenges:
- Intense competition in the drug discovery market.
- Dependence on successful partnerships for revenue generation.
- Regulatory hurdles and clinical trial risks.
Opportunities:
- Expansion into new therapeutic areas and modalities.
- Geographic expansion and partnerships in emerging markets.
- Leveraging technological advancements in AI and machine learning for drug discovery.
Recent Acquisitions (last 3 years):
- Acquisition of Just – Evotec Biologics II GmbH (2021) strengthened its biologics capabilities and expanded its manufacturing capacity.
- Acquisition of Rigontec GmbH (2020) added expertise in mRNA technology and expanded Evotec’s immunotherapy portfolio.
- Acquisition of Aptuit, LLC (2020) significantly increased Evotec’s global footprint and drug discovery capabilities.
AI-Based Fundamental Rating:
- Based on an AI-based analysis considering financial health, market position, and future prospects, Evotec SE ADR receives a rating of 7 out of 10.
- This rating indicates a strong company with promising growth potential, but potential risks due to market competition and dependence on partnerships.
Sources and Disclaimers:
- This analysis utilized information from Evotec SE ADR’s official website, financial reports, news articles, and industry research reports.
- This information is intended for educational purposes only and should not be considered financial advice.
Disclaimer:
This information is intended solely for educational purposes and should not be construed as financial advice.
About Evotec SE ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2009-12-04 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 5007 | Website https://www.evotec.com |
Full time employees 5007 | Website https://www.evotec.com |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.